A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay

Click to increase image sizeClick to decrease image size

Disclosure statement

Drs. Chase, Merryman, Fisher, LaCasce, Freedman, and Crombie have no disclosures. Dr. Jacobsen reports receiving consultancy from Acerta, Astra-Zeneca, and Merck; research funding from Pharmacyclics, F. Hoffmann-LaRoche, and Novartis; and honoraria from Takeda. Dr. Jacobsen reports consultancy from Kite, Celgene, Novartis, Bristol Myers Squibb, Nikarta, Precision Biosciences, and Humanigen; and grant funding from Pfizer. Dr. Davids reports consultancy from AbbVie, Adaptive Biotechnologies, Gilead Sciences, Janseen, Syros Pharmaceuticals, Rsearch to Practive, Beigene, and Celgene; and consultancy and grant funding from Ascentage Pharma, Astra-Zeneca, Genentech, MEI Pharma, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem. Dr. Brown reports consultancy from Novartis, Nextcea, Octapharma, Pfizer, Kite, Pharmacyclics, TG Therapeutics, Janssen, Genentech/Roche, and Teva; grant funding from Loxo and Sun; consultancy and grant funding from Gilead and Verastem; and safety monitoring board membership for Invectys and Morphosys. Ms. Jacob is a shareholder and employee of Adaptive Biotechnologies. Dr. Armand reports consultancy and reseach funding from Adaptive Biotechnologies, consultancy from Pfizer, Affimed, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, Miltenyi, Tessa, C4, GenMab, BMS, and Merck; research funding from Affimed, BMS, Merck, Roche, Tensha, Otsuka, Sigma Tau, Genentech, and IGM; and honoraria from BMS and Merck.